Logo

BNTC

Benitec Biopharma Inc.

BNTC

Benitec Biopharma Inc. • NASDAQ
$12.96 ▼ -0.42% (-0.06)
Market Cap $340.16 M
52w High $17.15
52w Low $9.49
Dividend Yield 0%
P/E -11.89
Volume 49.00K
Outstanding Shares 26.25M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $0 ▼ $14.652M ▼ $-13.563M ▲ 0% ▲ $-0.22 ▲ $-13.385M ▲
Q4-2025 $556K ▲ $17.454M ▲ $-16.147M ▼ -2.904K% ▼ $-0.39 ▼ $-19.02M ▼
Q3-2025 $0 $10.082M ▲ $-9.354M ▼ 0% $-0.24 ▲ $-9.248M ▼
Q2-2025 $0 $8.529M ▲ $-7.357M ▼ 0% $-0.33 ▲ $-7.276M ▼
Q1-2025 $0 $5.7M $-5.059M 0% $-0.48 $-4.968M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $94.479M ▼ $96.027M ▼ $2.428M ▲ $93.599M ▼
Q4-2025 $97.744M ▼ $99.592M ▼ $2.297M ▼ $97.295M ▼
Q3-2025 $103.583M ▲ $105.209M ▲ $7.639M ▲ $97.57M ▲
Q2-2025 $78.283M ▲ $79.068M ▲ $3.127M ▼ $75.941M ▲
Q1-2025 $67.841M $68.774M $4.594M $64.18M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-8.965M ▼ $-3.351M ▲ $0 ▲ $0 ▼ $-3.265M ▲ $-3.351M ▲
Q4-2025 $-8.805M ▲ $-8.529M ▼ $-466.437 ▲ $4.279M ▼ $-5.789M ▼ $-8.529M ▼
Q3-2025 $-9.354M ▼ $-3.086M ▲ $-6K ▲ $28.414M ▲ $25.301M ▲ $-3.092M ▲
Q2-2025 $-7.357M ▼ $-7.703M ▼ $-12K ▼ $17.872M ▼ $10.44M ▼ $-7.715M ▼
Q1-2025 $-5.059M $-4.586M $0 $21.655M $16.976M $-4.586M

Revenue by Products

Product Q1-2021Q2-2021Q3-2021
License
License
 $0 ▲$0 ▲$0 ▲
Royalty
Royalty
 $0 ▲$0 ▲$0 ▲
Service
Service
 $0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Benitec is still a pure R&D biotech story with no product sales yet. Its income statement is very simple: research and corporate costs going out, no commercial revenue coming in. Losses have been steady and relatively small in absolute terms, but they occur every year because the company is funding trials and platform work without any offsetting income. The large swings in earnings per share mostly reflect changes in the share count and reverse stock splits, not big changes in the underlying business. Financial performance will remain loss‑making until a partnership or product approval meaningfully changes the revenue picture.

Balance Sheet

Balance Sheet The balance sheet is very lean and almost entirely driven by cash and equity, with no financial debt. That is a positive in terms of not being burdened by interest payments, but the total asset base is small, which highlights how early stage the company is. Equity is positive but modest, and the long list of reverse splits suggests the company has repeatedly turned to equity markets to stay funded. Overall, this is a typical clinical‑stage biotech balance sheet: light on hard assets, reliant on cash on hand and future capital raises.

Cash Flow

Cash Flow Cash flow is consistently negative because the company spends on operations and clinical development without bringing in commercial cash. There is essentially no spending on large physical assets, so most cash burn goes directly into people, trials, and research. The burn rate looks controlled rather than explosive, but given the small cash base, even a modest ongoing outflow matters. Unless the company secures partnerships, grants, or new financing, cash could become a constraint on how aggressively it can run studies or expand its pipeline.

Competitive Edge

Competitive Edge Benitec’s competitive strength lies in being an early mover in a specialized form of gene silencing and replacement, focused initially on a rare disease with no approved disease‑modifying therapies. Its intellectual property around ddRNAi and the “silence and replace” concept, plus orphan and fast‑track regulatory designations, provide a meaningful edge in its chosen niche. At the same time, it is a very small player in a field that includes much larger, well‑funded gene therapy companies. The company’s dependence on a single lead program means its competitive position is tightly tied to how well that one therapy performs in trials.

Innovation and R&D

Innovation and R&D Innovation is the core of Benitec’s story. Its ddRNAi platform aims to turn a single treatment into a long‑lasting gene‑silencing and gene‑replacement therapy, which, if successful, would be a significant scientific achievement. Early trial results for the lead OPMD program appear encouraging on both safety and effectiveness, but they are based on a small number of patients and early‑stage data, so there is still substantial scientific and regulatory risk. The pipeline is currently narrow, centered on one main product, but the underlying platform looks adaptable to other rare genetic diseases. Future value from R&D will depend on turning this promising concept into larger, well‑controlled trial successes and then broadening the platform into additional indications or partnerships.

Summary

Benitec is a classic early‑stage biotech: highly innovative science, a focused clinical program, no revenue, and a modest financial base. On the strength side, it has a differentiated technology platform, encouraging initial data in a disease with few options, a clean balance sheet without debt, and intellectual property and regulatory designations that support its niche. On the risk side, it has a single lead asset, ongoing operating losses, and a history of relying on equity markets to fund operations, which brings dilution risk. The company’s future will largely hinge on two things: whether its lead therapy can keep delivering convincing clinical results, and whether it can secure enough capital or strategic partners to carry that program through later‑stage trials and eventually expand the platform beyond its first indication.

NEWS

November 14, 2025 · 5:00 PM UTC

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

Read more

November 6, 2025 · 12:19 AM UTC

Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering

Read more

November 5, 2025 · 4:43 PM UTC

Benitec Biopharma Inc. Announces Proposed Public Offering

Read more

November 3, 2025 · 7:10 AM UTC

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Read more

November 2, 2025 · 7:00 PM UTC

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

Read more